Electra Therapeutics (ETRA) Stock Price, News & Analysis

Company Overview

Electra Therapeutics, Inc. (NASDAQ: ETRA) is a clinical-stage biopharmaceutical company focused on developing therapies that modulate the immune system. The company’s research is directed toward selectively influencing immune-cell activity to address serious diseases, including cancer and autoimmune conditions.

Electra Therapeutics is advancing a pipeline of investigational medicines based on its immune-cell modulation approach. Its programs are intended to improve the body’s ability to recognize, control, or eliminate disease-associated cells while limiting effects on healthy tissue. The company’s candidates remain in clinical development and have not been established as approved treatments.

Electra Therapeutics is headquartered in the United States and operates primarily in the biotechnology and pharmaceutical sectors. Publicly available information provides limited detail about the company’s commercial operations, geographic reach, and current leadership.

Key Stats

• Today's Range: $8.36 to $8.83
• 50-Day Range: N/A
• 52-Week Range: $8.26 to $15.50
• Volume: 8,339 shs
• Average Volume: 486,344 shs
• Market Capitalization: $544.82 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $33.50
• Consensus Rating: Buy

Electra Therapeutics Stock Analysis - MarketRank™

Electra Therapeutics scored higher than 97% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Buy

Consensus Rating

Electra Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 strong buy rating, 5 buy ratings, 1 hold rating, and no sell ratings.

Upside Potential

Electra Therapeutics has a consensus price target of $33.50, representing about 293.2% upside from its current price of $8.52.

Amount of Analyst Coverage

Electra Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.7 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Electra Therapeutics are expected to grow in the coming year, from ($3.55) to ($2.05) per share.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.65% of the float of Electra Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Electra Therapeutics has a short interest ratio ("days to cover") of 0.79, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Electra Therapeutics has recently decreased by 41.71%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Electra Therapeutics does not currently pay a dividend.

Dividend Growth

Electra Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: 0.49

News Sentiment

Electra Therapeutics has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.59 average news sentiment score of companies.

News Coverage This Week

MarketBeat has tracked 11 news articles for Electra Therapeutics this week, compared to 3 articles on an average week.

Search Interest

5 people have searched for ETRA on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.

MarketBeat Follows

2 people have added Electra Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 3.6 / 5
• Insider Trading: Acquiring Shares

Cluster Insider Buying

2 insiders have purchased shares of Electra Therapeutics in the last three months. Multiple insiders buying is a strong bullish signal.

Net Insider Buying

Over the last three months, insiders have purchased a net $39,999,990.00 in company stock, which represents 7.4798% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Electra Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $39,999,990.00 in company stock and sold $0.00 in company stock.

Percentage Held by Institutions

Electra Therapeutics has minimal institutional ownership at this time.

Company Calendar

• Today: 10/28/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: N/A
• Industry: N/A
• Sub-Industry: N/A
• Current Symbol: NASDAQ:ETRA
• CIK: 2088082
• Web: www.electra-therapeutics.com
• Phone: 888-743-2290
• Fax: N/A
• Employees: 46
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Electra Therapeutics: $33.50
• High Price Target: $36.00
• Low Price Target: $30.00
• Potential Upside/Downside: +285.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 62,767,000
• Free Float: N/A
• Market Cap: $544.82 million
• Optionable: N/A
• Beta: N/A